mentrik.comAbout company
Mentrik Biotech, LLC is a private biopharmaceutical company that was incorporated in December 2010 and is headquartered in Dallas, TX. The goal of Mentrik Biotech is to optimize oncology-based therapeutics to treat patients with significant unmet medical need. Mentrik is developing AME-133v, a humanized, next-generation anti-CD20 monoclonal antibody. It is engineered for enhanced affinity to CD20 and increased antibody-dependent cell-mediated cytotoxicity (ADCC), and designed for improved treatment for low-affinity FcγRIIIa polymorphisms. Phase I/II trials in follicular lymphoma have been conducted in the US and Japan, and a Phase I trial in US rheumatoid arthritis patients. Continued Phase III development in relapsed follicular lymphoma patients is underway. Many patients relapse following current available treatments and a significant need for new effective treatment exists. Additional development in other oncology and rheumatology indications will also be pursued.
